"I believe this is a class effect," he said, meaning that the problem also applies to Celebrex and Pfizer's newer, similar drug, Bextra, which remain on the market.
"He did so voluntarily," the agency said.
The announcement comes just two weeks after Merck pulled its painkiller, Vioxx, which is in the same class of drugs as Bextra, from the market because a study showed that the risk of heart attacks doubled for patients who had taken Vioxx for 18 months or longer.
With Vioxx, researchers had been warning about the drug's possible cardiovascular risks since 2000, only a year after it was approved by the FDA.
